earnings
confidence high
sentiment positive
materiality 0.70
EyePoint Q1 net loss $45.2M; DURAVYU Phase 3 wet AMD enrollment over 90% in LUGANO, >50% in LUCIA
EyePoint, Inc.
2025-Q1 EPS reported
-$0.65
revenue$24,453,000
- Total net revenue $24.5M (up from $11.7M YoY); net loss $45.2M ($0.65 per share) vs $29.3M ($0.55) prior year.
- Cash, equivalents, and marketable securities $318.2M; runway into 2027 past Phase 3 topline data expected 2H 2026.
- LUGANO trial >90% enrolled, LUCIA >50%; enrollment on track to complete 2H 2025.
- Phase 2 VERONA in DME met endpoints; subgroup showed BCVA +10.3 letters vs +3.0 for aflibercept at week 24.